Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2

Area of Science:

• Genetics and rare diseases
• Oncology
• Neurology

Background:

• Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder characterized by bilateral vestibular schwannomas and other central nervous system tumors.
• NF2 presents significant morbidity due to tumor progression and surgical interventions, highlighting an unmet medical need.
• Current therapeutic options for NF2 are limited, necessitating the development of novel treatment strategies.

Framework:

• Recommendations for accelerating NF2 clinical trials were developed through a consensus workshop.
• The workshop convened 36 international experts, including researchers, clinicians, industry representatives, and patient advocates.
• Key focus areas included identifying obstacles to NF2 trials and exploring the therapeutic pipeline.

Implementation:

• Consensus was reached that the current scientific understanding supports the initiation of NF2 clinical trials.
• Strategies to overcome challenges in NF2 trial design and execution were discussed.
• Candidate therapeutics for NF2 were evaluated for their potential in clinical development.

Implications:

• Phase 0 and Phase II clinical trials represent near-term opportunities for NF2 therapeutic development.
• Successful patient recruitment for NF2 trials necessitates strong collaboration among NF2 clinics.
• These recommendations aim to expedite the translation of research findings into effective treatments for NF2 patients.